Potential drug-drug and herb-drug interactions in patients with cancer: A prospective study of medication surveillance

Journal of Oncology Practice

Volumn 13, Issue 7, 2017, Pages e613-e620

  Ramos Esquivel, Allan ^a,b   Víquez Jaikel, Alvaro ^a,b   Fernández, Cristina ^a,b  

^a HOSPITAL SAN JUAN DE DIOS   (Costa Rica)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CARBAMAZEPINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DEXTROMETHORPHAN; DOCETAXEL; EFAVIRENZ; FLUOROURACIL; FLUOXETINE; GLIBENCLAMIDE; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; IBUPROFEN; IMATINIB; IRBESARTAN; LORATADINE; METHOTREXATE; NON PRESCRIPTION DRUG; NUTRITION SUPPLEMENT; PACLITAXEL; PARACETAMOL; PHENYTOIN; SORAFENIB; TAMOXIFEN; UNINDEXED DRUG; WARFARIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOE; ALOE CAPENSIS; ALOE VERA; ANNONA MURICATA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CAMELLIA SINENSIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; ECCHINACEA ANGUSTFOLIA; FEMALE; GARLIC; GASTROINTESTINAL STROMAL TUMOR; GINKGO BILOBA; GINSENG; GLIOMA; GRAPE; HEMATOLOGIC MALIGNANCY; HERB DRUG INTERACTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MATRICARIA RECUTITA; MEDICINAL PLANT; MIDDLE AGED; MORINGA OLEIFERA; NEOADJUVANT CHEMOTHERAPY; NEUROENDOCRINE TUMOR; ONCOLOGIST; ORAL MUCOSITIS; OVARY CANCER; PHARMACIST; PRESCRIPTION; PROSPECTIVE STUDY; PROSTATE CANCER; SIDE EFFECT; SPIRULINA; STOMACH CANCER; UNCARIA TOMENTOSA; VALERIANA OFFICINALIS; ADVERSE DRUG REACTION; AGED; DIETARY SUPPLEMENT; MEDICATION THERAPY MANAGEMENT; NEOPLASM; QUESTIONNAIRE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NEOPLASMS; NONPRESCRIPTION DRUGS; PHARMACISTS; SURVEYS AND QUESTIONNAIRES;

EID: 85026830580     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2017.020859     Document Type: Conference Paper

References (23)

1. Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer 6: 546-558, 2006
2. Riechelmann RP, Tannock IF, Wang L, et al: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592-600, 2007
3. van Leeuwen RW, Swart EL, Boven E, et al: Potential drug interactions in cancer therapy: A prevalence study using an advanced screening method. Ann Oncol 22: 2334-2341, 2011
4. McCune JS, Hatfield AJ, Blackburn AA, et al: Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12:454-462, 2004
5. Kelly JP, Kaufman DW, Kelley K, et al: Use of herbal/natural supplements according to racial/ethnic group. J Altern Complement Med 12:555-561, 2006
6. Drugs.com: Drug interaction checker. https://www.drugs.com/drug-interactions. html
7. Memorial Sloan Kettering Cancer Center: Search about herbs. https://www. mskcc.org/cancer-care/treatments/symptom-management/integrative-medicine/herbs/ search
8. Natural Medicines Comprehensive Database. http://naturaldatabase.therapeutic research.com
9. Barrons R: Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61:380-385, 2004
10. Scheife RT, Hines LE, Boyce RD, et al: Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 38:197-206, 2015
11. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245, 1981
12. van Leeuwen RW, Jansman FG, van den Bemt PM, et al: Drug-drug interactions in patients treated for cancer: A prospective study on clinical interventions. Ann Oncol 26:992-997, 2015
13. Stoll P, Kopittke L: Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: A prospective cohort study. Int J Clin Pharm 37: 475-484, 2015
14. van Leeuwen RW, Brundel DH, Neef C, et al: Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108: 1071-1078, 2013
15. Bossaer JB, Thomas CM: Drug interaction database sensitivity with oral antineoplastics: An exploratory analysis. J Oncol Pract 13:e217-e222, 2017
16. Miranda V, Fede A, Nobuo M, et al: Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage 42:342-353, 2011
17. Buajordet I, Ebbesen J, Erikssen J, et al: Fatal adverse drug events: The paradox of drug treatment. J Intern Med 250:327-341, 2001
18. Leveque D, Delpeuch A, Gourieux B: New anticancer agents: Role of clinical pharmacy services. Anticancer Res 34:1573-1578, 2014
19. Alsanad SM, Howard RL, Williamson EM: An assessment of the impact of herbdrug combinations used by cancer patients. BMC Complement Altern Med 16:393, 2016
20. Greenlee H, Neugut AI, Falci L, et al: Association between complementary and alternative medicine use and breast cancer chemotherapy initiation: The Breast Cancer Quality of Care (BQUAL) study. JAMA Oncol 2:1170-1176, 2016
21. Horneber M, Bueschel G, Dennert G, et al: How many cancer patients use complementary and alternative medicine: A systematic review and metaanalysis. Integr Cancer Ther 11:187-203, 2012
22. Lee RT, Barbo A, Lopez G, et al: National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol 32:4095-4101, 2014
23. Riechelmann RP, Del Giglio A: Drug interactions in oncology: How common are they? Ann Oncol 20:1907-1912, 2009